Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial
We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, bu...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2005-03, Vol.40 (5), p.745-749 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 749 |
|---|---|
| container_issue | 5 |
| container_start_page | 745 |
| container_title | Clinical infectious diseases |
| container_volume | 40 |
| creator | Gavrila, Alina Hsu, William Tsiodras, Sotirios Doweiko, John Gautam, Shiva Martin, Lizabeth Moses, Alan C Karchmer, Adolf W Mantzoros, Christos S |
| description | We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period. |
| doi_str_mv | 10.1086/427697 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17809279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17809279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-91046db43d67855968fba67007e7fbb264776ee18f55c7d0d8c2d18cf1a5a7eb3</originalsourceid><addsrcrecordid>eNpFUctu1TAQtRCIlgKfgLxi1YCdxI-wQxWPSpXYwDryY9xr5NjBdgrpT_JL-NIrdTGaGc2Zc0ZzEHpNyTtKJH8_9oJP4gk6p2wQHWcTfdpqwmQ3ykGeoRel_CSEUknYc3RGmaDj2A_n6O_1suZ0BwvEin3EB397CDtWpvo7wCpWn6E2gM8q4HqArNa989FuBixeoCqdgje47NHmtADWO64ZVP3P99vXA159ug2-qvsU23irOKbTxEFMzuusKnzACvf4TwvXpFP2KlzirKJNi78He4lt2nSAToemfezXoAzo1JkU23khtGvqcesleuZUKPDqlC_Qj8-fvl997W6-fbm--njTmWEktZsoGbnV42C5kIxNXDqtuCBEgHBa93wUggNQ6RgzwhIrTW-pNI4qpgTo4QK9feBt3_u1Qanz4ouBEFSEtJWZCkmmXkyPQJNTKRncvGa_qLzPlMxH6-YH6xrwzYlx0wvYR9jJq-EfvceYsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17809279</pqid></control><display><type>article</type><title>Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gavrila, Alina ; Hsu, William ; Tsiodras, Sotirios ; Doweiko, John ; Gautam, Shiva ; Martin, Lizabeth ; Moses, Alan C ; Karchmer, Adolf W ; Mantzoros, Christos S</creator><creatorcontrib>Gavrila, Alina ; Hsu, William ; Tsiodras, Sotirios ; Doweiko, John ; Gautam, Shiva ; Martin, Lizabeth ; Moses, Alan C ; Karchmer, Adolf W ; Mantzoros, Christos S</creatorcontrib><description>We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/427697</identifier><identifier>PMID: 15714423</identifier><language>eng</language><publisher>United States</publisher><subject>Anti-HIV Agents - adverse effects ; Antiretroviral Therapy, Highly Active - adverse effects ; Double-Blind Method ; Fenofibrate - therapeutic use ; Human immunodeficiency virus ; Humans ; Hypoglycemic Agents - therapeutic use ; Hypolipidemic Agents - therapeutic use ; Metabolic Syndrome - chemically induced ; Metabolic Syndrome - drug therapy ; Thiazolidinediones - therapeutic use</subject><ispartof>Clinical infectious diseases, 2005-03, Vol.40 (5), p.745-749</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-91046db43d67855968fba67007e7fbb264776ee18f55c7d0d8c2d18cf1a5a7eb3</citedby><cites>FETCH-LOGICAL-c340t-91046db43d67855968fba67007e7fbb264776ee18f55c7d0d8c2d18cf1a5a7eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15714423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gavrila, Alina</creatorcontrib><creatorcontrib>Hsu, William</creatorcontrib><creatorcontrib>Tsiodras, Sotirios</creatorcontrib><creatorcontrib>Doweiko, John</creatorcontrib><creatorcontrib>Gautam, Shiva</creatorcontrib><creatorcontrib>Martin, Lizabeth</creatorcontrib><creatorcontrib>Moses, Alan C</creatorcontrib><creatorcontrib>Karchmer, Adolf W</creatorcontrib><creatorcontrib>Mantzoros, Christos S</creatorcontrib><title>Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.</description><subject>Anti-HIV Agents - adverse effects</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Double-Blind Method</subject><subject>Fenofibrate - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Metabolic Syndrome - chemically induced</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Thiazolidinediones - therapeutic use</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUctu1TAQtRCIlgKfgLxi1YCdxI-wQxWPSpXYwDryY9xr5NjBdgrpT_JL-NIrdTGaGc2Zc0ZzEHpNyTtKJH8_9oJP4gk6p2wQHWcTfdpqwmQ3ykGeoRel_CSEUknYc3RGmaDj2A_n6O_1suZ0BwvEin3EB397CDtWpvo7wCpWn6E2gM8q4HqArNa989FuBixeoCqdgje47NHmtADWO64ZVP3P99vXA159ug2-qvsU23irOKbTxEFMzuusKnzACvf4TwvXpFP2KlzirKJNi78He4lt2nSAToemfezXoAzo1JkU23khtGvqcesleuZUKPDqlC_Qj8-fvl997W6-fbm--njTmWEktZsoGbnV42C5kIxNXDqtuCBEgHBa93wUggNQ6RgzwhIrTW-pNI4qpgTo4QK9feBt3_u1Qanz4ouBEFSEtJWZCkmmXkyPQJNTKRncvGa_qLzPlMxH6-YH6xrwzYlx0wvYR9jJq-EfvceYsQ</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>Gavrila, Alina</creator><creator>Hsu, William</creator><creator>Tsiodras, Sotirios</creator><creator>Doweiko, John</creator><creator>Gautam, Shiva</creator><creator>Martin, Lizabeth</creator><creator>Moses, Alan C</creator><creator>Karchmer, Adolf W</creator><creator>Mantzoros, Christos S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20050301</creationdate><title>Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial</title><author>Gavrila, Alina ; Hsu, William ; Tsiodras, Sotirios ; Doweiko, John ; Gautam, Shiva ; Martin, Lizabeth ; Moses, Alan C ; Karchmer, Adolf W ; Mantzoros, Christos S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-91046db43d67855968fba67007e7fbb264776ee18f55c7d0d8c2d18cf1a5a7eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anti-HIV Agents - adverse effects</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Double-Blind Method</topic><topic>Fenofibrate - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Metabolic Syndrome - chemically induced</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Thiazolidinediones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gavrila, Alina</creatorcontrib><creatorcontrib>Hsu, William</creatorcontrib><creatorcontrib>Tsiodras, Sotirios</creatorcontrib><creatorcontrib>Doweiko, John</creatorcontrib><creatorcontrib>Gautam, Shiva</creatorcontrib><creatorcontrib>Martin, Lizabeth</creatorcontrib><creatorcontrib>Moses, Alan C</creatorcontrib><creatorcontrib>Karchmer, Adolf W</creatorcontrib><creatorcontrib>Mantzoros, Christos S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gavrila, Alina</au><au>Hsu, William</au><au>Tsiodras, Sotirios</au><au>Doweiko, John</au><au>Gautam, Shiva</au><au>Martin, Lizabeth</au><au>Moses, Alan C</au><au>Karchmer, Adolf W</au><au>Mantzoros, Christos S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2005-03-01</date><risdate>2005</risdate><volume>40</volume><issue>5</issue><spage>745</spage><epage>749</epage><pages>745-749</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.</abstract><cop>United States</cop><pmid>15714423</pmid><doi>10.1086/427697</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2005-03, Vol.40 (5), p.745-749 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17809279 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Anti-HIV Agents - adverse effects Antiretroviral Therapy, Highly Active - adverse effects Double-Blind Method Fenofibrate - therapeutic use Human immunodeficiency virus Humans Hypoglycemic Agents - therapeutic use Hypolipidemic Agents - therapeutic use Metabolic Syndrome - chemically induced Metabolic Syndrome - drug therapy Thiazolidinediones - therapeutic use |
| title | Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20in%20highly%20active%20antiretroviral%20therapy-induced%20metabolic%20syndrome%20by%20treatment%20with%20pioglitazone%20but%20not%20with%20fenofibrate:%20a%202%20x%202%20factorial,%20randomized,%20double-blinded,%20placebo-controlled%20trial&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Gavrila,%20Alina&rft.date=2005-03-01&rft.volume=40&rft.issue=5&rft.spage=745&rft.epage=749&rft.pages=745-749&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/427697&rft_dat=%3Cproquest_cross%3E17809279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17809279&rft_id=info:pmid/15714423&rfr_iscdi=true |